Pain Outcomes Associated With Exogenous Hormone Therapy in Adults

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
University of Kansas Medical Center
Study ID
NCT06939257
Status
Recruiting
Apply to this trial

Conditions

  • Gender Minority Individuals
  • Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Study Details

TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of surveys, quantitative sensory testing (QST), brain MRIs, and qualitative interviews. Following recruitment and consent, participants will complete baseline survey measures and will repeat those measures at 1 months, 3 month, 6 months, and 12 months. QST measures, brain MRIs, and Qualitative Interviews will be offered to participants in cohort (1) and will be completed at baseline and 12 months.

Key Dates

Start date
Mar 31, 2025
Status verified
May 2026
Primary completion
Sep 16, 2029
Completion
Sep 16, 2029

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Persons Initiating GHT
  • Arm: Gender Minority Persons Not Taking GHT

Primary Outcome Measure

Prevalence of Chronic Pain in Gender Minority Adults Initiating GHT [ Time Frame: Baseline and 1, 3, 6, and 12-months. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Kansas Medical CenterKansas CityKansas66160
Miranda McMillan, MSc
[email protected]
913-588-7630
Andrea L Chadwick, MD, MSc, FASA (PRINCIPAL_INVESTIGATOR)

Find similar trials in Kansas City, KS

By research site
The University of Kansas Medical Center· Kansas City, KS

Related Studies